ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology1995
Lack of serotype-specific antibody response to lipopolysaccharide antigens of Moraxella catarrhalis during lower respiratory tract infection.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 30 citations in OpenAlex.
- Potential targets for next generation antimicrobial glycoconjugate vaccines.FEMS microbiology reviews · 2018Review
- Mutant lipooligosaccharide-based conjugate vaccine demonstrates a broad-spectrum effectiveness against Moraxella catarrhalis.Vaccine · 2011Article
- Use of Moraxella catarrhalis lipooligosaccharide mutants to identify specific oligosaccharide epitopes recognized by human serum antibodies.Infection and immunity · 2009Article
- Galactose residues on the lipooligosaccharide of Moraxella catarrhalis 26404 form the epitope recognized by the bactericidal antiserum from conjugate vaccination.Infection and immunity · 2008Article
- Biological and immunological characteristics of lipooligosaccharide-based conjugate vaccines for serotype C Moraxella catarrhalis.Infection and immunity · 2007Article
- Characterization of a cluster of three glycosyltransferase enzymes essential for Moraxella catarrhalis lipooligosaccharide assembly.Journal of bacteriology · 2005Article
- Synthesis and characterization of lipooligosaccharide-based conjugate vaccines for serotype B Moraxella catarrhalis.Infection and immunity · 2005Article
- Identification of a 3-deoxy-D-manno-octulosonic acid biosynthetic operon in Moraxella catarrhalis and analysis of a KdsA-deficient isogenic mutant.Infection and immunity · 2003Article
- Specific immune responses and enhancement of murine pulmonary clearance of Moraxella catarrhalis by intranasal immunization with a detoxified lipooligosaccharide conjugate vaccine.Infection and immunity · 2002Article
- Moraxella catarrhalis: from emerging to established pathogen.Clinical microbiology reviews · 2002Review
- Functional characteristics of a protective monoclonal antibody against serotype A and C lipooligosaccharides from Moraxella catarrhalis.Infection and immunity · 2001Article
- Lipooligosaccharide P(k) (Galalpha1-4Galbeta1-4Glc) epitope of moraxella catarrhalis is a factor in resistance to bactericidal activity mediated by normal human serum.Infection and immunity · 2000Article
- Enhancement of clearance of bacteria from murine lungs by immunization with detoxified lipooligosaccharide from Moraxella catarrhalis conjugated to proteins.Infection and immunity · 2000Article
- Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis.Infection and immunity · 1998Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An enzyme immunoassay (EIA) was used to determine the antibody response to different serotypes of lipopolysaccharide (LPS) antigens of Moraxella catarrhalis in adult patients with lower respiratory tract infections (LRTI). Moraxella catarrhalis was isolated from sputum or nasopharyngeal samples from 20 patients with LRTI. Sixteen of the isolates were serotype A, four were type B and none were type C. The antibody response to the different LPS serotypes was determined in paired sera from patients suffering from LRTI. In addition to the 20 patients with Moraxella catarrhalis isolated (Group 1), a group of seven patients with LRTI of unknown etiology (Group 2) and a group of ten patients with LRTI of known other bacterial etiology (Group 3) were selected for this study. An increase in antibody levels of > 1.5-fold (convalescent-/acute-phase serum) was recorded in approximately half of the patients, not only in the first group (Moraxella catarrhalis isolated) but also in the other two groups. However, in the first and second groups there was a correlation between an increase in antibody levels in the LPS EIA and in an EIA using whole bacterial cells as antigen. In the group of patients in whom Moraxella catarrhalis was isolated, the antibody response to LPS antigens was not serotype specific. The antibody response to type-A and type-B LPS was more predominant than the response to type-C LPS in most patients.(ABSTRACT TRUNCATED AT 250 WORDS)
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.